December 5, 2022 —  -Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has entered into a research partnership with U.S.


Here is a recap of what ITN viewers found most interesting during the month of November:

1. Top 10 Predictions for Modality Trends, AI and Imaging IT at RSNA 2022

2. What’s Next for AI Regulations in Medical Imaging?

December 3, 2022 — Results from its Orviglance Food Effect study were presented by Ascelia Pharma, a biopharmaceutical company focused on improving the lives of people with rare cancers, during RSNA 2022, the Radiological Society of North America Scientific Assembly and Annual Meeting, which took place Nov. 27-Dec. 1, 2022, in Chicago, IL.

December 2, 2022 —  Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced topline results from its Phase 3 LIGHTHOUSE trial that evaluated the diagnostic performance and safety of 18F-rhPSMA-7.3 in newly diagnosed prostate cancer. 18F-rhPSMA-7.3 is an investigational high affinity radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted PET imaging agent.

December 2, 2022 —  New CT technology outperforms conventional CT in detecting subtle damage in the lungs of patients with persistent symptoms of COVID-19, according to a new study published in 

December 1, 2022 —  A new method for determining whether patients with heart disease need coronary stents or bypass surgery is more effective than the angiogram, which is currently used, according to research from UTHealth Houston Heart & Vascular. 

December 1, 2022 — At the 2022 Radiological Society of North America (RSNA) Annual Meeting, Peter R.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now